Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00288158 · ClinicalTrials.gov registry record · Phase 2

Primary Prevention of Hypertension in Obese Adolescents

A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT00288158: Completed Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NCT00288158 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00288158, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: 1. Test the hypothesis that lowering uric acid will improve endothelial function. 2. Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels. 3. Test the hypothesis that lowering uric acid will reduce markers of inflammation

Interventions

  • DRUG Placebo
  • DRUG Allopurinol
  • DRUG Probenecid

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2008-09
Est. Completion 2011-01
Phase Phase 2

What the finished NCT00288158 record still lists

NCT00288158 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00288158 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00288158 about?

NCT00288158 is a clinical study titled "Primary Prevention of Hypertension in Obese Adolescents". The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: 1. Test the hypothesis that lowering uric acid will improve endothelial fu...

What is the current status of trial NCT00288158?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-09. Estimated completion is 2011-01.

What interventions are being tested in trial NCT00288158?

The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Probenecid (DRUG).

Who is sponsoring clinical trial NCT00288158?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00288158's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00288158, the US trial registry maintained by the National Library of Medicine. NCT00288158 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.